kulahan 2 days ago

Oh sick, so every time my company faces an economic downturn, I can shift huge amounts of workers to a program designed to sell unfinished drugs at cost! Like, it doesn’t even have to be viable, just start selling saline with coloring or something.

Unless it does have to be somewhat viable, which is… regulation.

Reply View 1 reply
  • DennisP 2 days ago

    I'm not against regulation in principle. In this case, full disclosure of exactly what's in the drug should definitely be required. People's doctors can make informed decisions after that.

    Restricting this to patients who are otherwise out of options is probably also a good idea. Pancreatic cancer would certainly qualify.

    Reply View 0 replies
Induane 3 days ago

Ding ding ding this is the way. Sell at cost. Real cost, like cost of making. NOT a cost that includes R&S amortized across the batch.

Reply View 5 replies
  • vibrio 3 days ago

    Not even cost plus? Not sure how that works, from the viewpoint of economic incentives.

    Reply View 4 replies
    • ulfw 2 days ago

      It's literally free data for efficacy / later sales.

      Reply View 3 replies
      • vibrio 2 days ago

        So charging patients/insurance companies at cost to fund the clinical studies?

        Reply View 2 replies